| Literature DB >> 29949664 |
Carina Scholtysek1,2, Natacha Ipseiz3, Christina Böhm1,2, Brenda Krishnacoumar1,2, Martin Stenzel1,2, Tina Czerwinski4, Katrin Palumbo-Zerr1,2, Tobias Rothe1,2, Daniela Weidner1,2, Alexandra Klej1,2, Cornelia Stoll1,2, Jörg Distler1, Jan Tuckermann5, Martin Herrmann1, Ben Fabry4, Wolfgang H Goldmann4, Georg Schett1, Gerhard Krönke1,2.
Abstract
NR4A1 (Nur77 or NGFI-B), an orphan member of the nuclear receptor superfamily, has been identified as a key regulator of the differentiation and function of myeloid, lymphoid, and mesenchymal cells. The detailed role of NR4A1 in bone biology is incompletely understood. Here, we report a role for NR4A1 as novel factor controlling the migration and recruitment of osteoclast precursors during bone remodeling. Myeloid-specific but not osteoblast-specific deletion of NR4A1 resulted in osteopenia due to an increase in the number of bone-lining osteoclasts. Although NR4A1-deficient osteoclast precursors displayed a regular differentiation into mature osteoclasts, they showed a hyper-motile phenotype that was largely dependent on increased osteopontin expression, suggesting that expression of NR4A1 negatively controlled osteopontin-mediated recruitment of osteoclast precursors to the trabecular bone. Pharmacological activation of NR4A1, in turn, inhibited osteopontin expression and osteopontin-dependent migration of osteoclast precursors resulted in reduced abundance of bone-resorbing osteoclasts in vivo as well as in an ameliorated bone loss after ovariectomy in mice. This study identifies NR4A1 as a crucial player in the regulation of osteoclast biology and bone remodeling and highlights this nuclear receptor as a promising target for therapeutic intervention during the treatment of osteoporosis.Entities:
Keywords: CELL MIGRATION; NUCLEAR RECEPTORS; OSTEOCLASTS; OSTEOIMMUNOLOGY; OSTEOPOROSIS
Mesh:
Substances:
Year: 2018 PMID: 29949664 DOI: 10.1002/jbmr.3533
Source DB: PubMed Journal: J Bone Miner Res ISSN: 0884-0431 Impact factor: 6.741